Topics, Trends & Updates

November 2025

View as web page
YouTube  Facebook  Linkedin  Instagram

Updated: PrEP to Prevent HIV and Promote Sexual Health

Updated by lead authors Dr. Rona M. Vail and Aviva Cantor, with the Medical Care Criteria Committee (MCCC), the PrEP to Prevent HIV and Promote Sexual Health guideline was developed to help clinicians successfully start and continue pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring HIV.


Comprehensive updates to this guideline include:


  • Recommendations and text added throughout on subcutaneous lenacapavir (SC LEN) as PrEP
  • Text added throughout on tenofovir alafenamide/emtricitabine (TAF/FTC) as an alternative PrEP option for HIV exposures through receptive vaginal sex for individuals in whom tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is not tolerated or not desired
  • Choosing and Prescribing a PrEP Regimen > Alternative Oral Dosing: On-Demand PrEP section: Text added on “2-1-1-1” on-demand dosing of TDF/FTC for receptive vaginal HIV exposures


Go to full guideline

Contents:

Updated: Therapeutic Use of Medical Cannabis in New York State

Updated by lead authors Drs. Deepika Slawek and Julia H. Arnsten, with the Substance Use Guidelines Committee, the Therapeutic Use of Medical Cannabis in New York State guideline was developed to increase access to evidence-based guidance and provide clinicians with a framework for implementing the use of medical cannabis in outpatient settings.


Updates to this guideline include:


  • Updated information related to New York State Office of Cannabis Management and Medical Cannabis Program, including on patient medical cannabis certification
  • Updated information and guidance on dabs and waxes as nonrecommended administration methods
  • Therapeutic Uses of Cannabis section:
  • Updated Box 2: Examples of Conditions for Medical Cannabis Use in New York State
  • Updated information on chronic or severe pain, post-traumatic stress disorder, and opioid use disorder as indications for medical cannabis use
  • Assessment section:
  • Updated information on conditions that require caution
  • New Table 3: Drug-Drug Interactions
  • Medical Cannabis Initiation section: Updated information on medical cannabis use during pregnancy
  • Monitoring section: New recommendation added and updated information on urine toxicology testing


Go to full guideline

Contents:

Updated: Virologic and Immunologic Monitoring in HIV Care

Updated by lead authors Shanmukha Priya Peddireddy, Dr. Hector I. Ojeda-Martinez, and Dr. Christine A. Kerr, with the MCCC, the Virologic and Immunologic Monitoring in HIV Care guideline was developed to provide evidence-based recommendations to clinicians who provide ambulatory care to patients with HIV.


Updates to this guideline include:



Go to full guideline

Contents:

Hot Topics


See all Hot Topics

Don't Miss

Updated: Drug-Drug Interaction Guide: From HIV Prevention to Treatment

Viremic—Cases in HIV Podcast

Join Hosts Eileen Scully and Christopher Hoffmann as they present cases, explore quandaries in adult HIV care, and discuss key evidence and guidelines that inform clinical decision-making.



New Episodes

Case 8. Charting a Path Forward: Subspecialists request simplified ART for a 56-year-old woman with a long ART history, who is taking a DOAC, has evolving renal function, and some drug resistance. Which factors to prioritize? Eileen and Chris have some, but not a complete, medical history. Listen as they work through the information they do have, consider 7 questions key in making an ART switch, and evaluate the available options. Listen Now

Case 9. A New TRIO to Reduce ART Complexity: A 62-year-old patient with HIV for ~40 years presents on the life-saving TRIO regimen after a beloved care provider retires. Will a switch improve his quality of life? Eileen and Chris suspect that a change to a once-a-day regimen with fewer pills will maintain his viral suppression and make life easier, but the TRIO regimen inspires dedication in many long-term patients. Would he be open to a switch? Would it confer other benefits? Listen as Eileen and Chris consider the necessity of switch and plot a treatment course. Listen Now

Coming Soon

Case 10. A Growing Problem: ART-Associated Weight Gain: A 54-year-old woman with longstanding HIV and obesity is stable on ART but concerned that it is causing weight gain. How best to address this growing concern? Listen as Chris and Eileen decipher the evidence related to weight gain and ART and weigh the best strategies for addressing this increasingly common and social media-inflected concern for patients with HIV and their care providers. Listen November 11

We’re open to suggestions! To submit a clinical topic for a Viremic case discussion, email us at viremicpodcast@jh.edu.

Conversations With CEI Podcast

Recap of the 2025 Annual New York State Hepatitis C and Drug User Health Conference: On September 9th, CEI hosted its first in-person conference dedicated to hepatitis C and drug user health. A group of New York State-based clinicians met in Catskill for a full-day agenda focused on (1) integrating wellness into clinical practice as a way to improve patient care and outcomes, and (2) innovative decision-making frameworks to help clinicians navigate complex scenarios in the absence of strong formal evidence, like clinical guidelines and peer-reviewed studies. This episode of Conversations with CEI features conference planner and facilitator Taylor Edelmann—an

educator and consultant working at the intersection of LGBTQIA+ health, drug user health and harm reduction—sharing his experience and insights about the day. Listen Now

Upcoming Training, Education, and Events

CEI:

See all


General:

See all
 

Are You a Subscriber?



If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program Topics, Trends, and Updates newsletter every month and stay current with new and updated guidelines. We send 1 email per month and do not share our mailing list.

Comments? Questions? Suggestions?


Email us: aiguidelines@jhmi.edu. 

We'll get back to you as quickly as possible.


Note that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice. 
 
 

Clinical Guidelines Program at JHU | Carnegie 3, Rm 386, 600 North Wolfe Street | Baltimore, MD 21287-0014 US

Unsubscribe | Update Profile | Constant Contact Data Notice

Constant Contact